Investigational Drug Information for GDC-9545
✉ Email this page to a colleague
What is the drug development status for GDC-9545?
GDC-9545 is an investigational drug.
There have been 15 clinical trials for GDC-9545.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2022.
The most common disease conditions in clinical trials are Breast Neoplasms, Endometrial Neoplasms, and [disabled in preview]. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and MedSIR.
There is one US patent protecting this investigational drug and thirty-one international patents.
Summary for GDC-9545
| US Patents | 1 |
| International Patents | 31 |
| US Patent Applications | 22 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 1 (2022-06-01) |
| Vendors | 26 |
Recent Clinical Trials for GDC-9545
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Hoffmann-La Roche | Phase 3 |
| A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population | MedSIR | Phase 2 |
| Preoperative Window of Opportunity Study With Giredestrant (GDC-9545) or Tamoxifen in Premenopausal Women With ER[+]/HER2[-] & Ki67≥10% Early Breast Cancer | MedSIR | Phase 2 |
Clinical Trial Summary for GDC-9545
Top disease conditions for GDC-9545
Top clinical trial sponsors for GDC-9545
US Patents for GDC-9545
International Patents for GDC-9545
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GDC-9545 | Argentina | AR103081 | 2034-12-18 | ⤷ Sign Up |
| GDC-9545 | Australia | AU2015367509 | 2034-12-18 | ⤷ Sign Up |
| GDC-9545 | Australia | AU2020200407 | 2034-12-18 | ⤷ Sign Up |
| GDC-9545 | Brazil | BR112017007662 | 2034-12-18 | ⤷ Sign Up |
| GDC-9545 | Canada | CA2963736 | 2034-12-18 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
